Document:

EXHIBIT 10.69

June 29, 1999

Via Federal Express

Mr. Jim O'Shea
Chairman, President and CEO
Bioject Inc.

7620S.W. Bridgeport Road
Portland, Oregon 97224

Re:  Binding Letter Agreement

Dear Mr. O'Shea:

We are pleased to have reached an  agreement  in principle  with Bioject for the
development by Bioject of a disposable, prefilled needle-free injector for Amgen
pursuant to the following terms of this Binding Letter Agreement:

1. Within fifteen (15) days of the execution of this Binding  Letter  Agreement,
Amgen shall pay to Bioject a one-time sum of $250,000. In consideration thereof,
Bioject shall:

     (a) not negotiate with,  solicit offers from, or hold discussions with, any
     third party,  in any territory,  regarding the development of a disposable,
     needle-free injector for use in the treatment of *** and/or *** ("Exclusive
     Negotiation")  for the  period  beginning  as of the  date of this  Binding
     Letter  Agreement  and ending on the later of: (i) August 31, 1999, or (ii)
     five (5) business days following  delivery of the deliverables set forth in
     paragraph 1(b) below, but in no case later than March 31, 2000; and

     (b) develop a  disposable,  prefilled  needle-free  injector and deliver to
     Amgen the first set of deliverables  set forth on Schedule "A" hereto on or
     before August 31, 1999.

     * It is understood and agreed by the parties that the aforesaid  payment by
     Amgen of $250,000 is apportioned as follows: (i) $100,000 for the Exclusive
     Negotiation  period  through  August 31,  1999,  and (ii)  $150,000 for the
     development and deliverables.

2. On or before the later of (i) August 31, 1999, or (ii) five (5) business days
following  delivery of the deliverables set forth in paragraph 1(b) above, Amgen
may elect to extend the  Exclusive  Negotiation  period and the  development  by
giving  written notice to Bioject of its intention to do so, in which case Amgen
shall,  within  fifteen (15) days of such notice,  pay to Bioject an  additional
one-time sum of $250,000, and Bioject shall:

     (a) extend the Exclusive  Negotiation  period up to and including the later
     of: (i) December 31, 1999, or (ii) fifteen (15) days following delivery of

                                       1

*** Confidential  portions omitted pursuant to a confidential  treatment request
submitted  pursuant to Rule 24b-2 under the Securities  Exchange Act of 1934, as
amended.  Omitted  portions have been filed  separately  with the Securities and
Exchange Commission.

<PAGE>

     the  deliverables  set forth in paragraph 2(b) below,  but in no case later
     than March 31, 2000; and

     (b) continue  development of a disposable,  prefilled  needle-free injector
     and deliver to Amgen the second set of  deliverables  set forth on Schedule
     "A" hereto on or before December 31, 1999.

     * It is understood and agreed by the parties that the aforesaid  payment by
     Amgen of $250,000 is apportioned as follows: (i) $100,000 for the extension
     of  Exclusive  Negotiation  period  through  December  31,  1999,  and (ii)
     $150,000 for the development and deliverables.

3. During the  Exclusive  Negotiation  period,  at Amgen's sole  discretion  and
option,  the  parties  shall  negotiate  in good  faith  toward  execution  of a
definitive agreement for the potential future development, license and supply by
Bioject to Amgen of disposable, prefilled needle-free injectors.

4. Any intellectual property and/or know-how arising out of the development work
provided for in  paragraphs  1(b) and 2(b) above shall be  exclusively  owned by
Bioject;  provided,  however,  that any industrial designs  contributed by Amgen
shall be exclusively owned by Amgen.

5. In the  event  that  Bioject  fails to  deliver  any or all of the  aforesaid
deliverables,  Bioject  shall  refund to Amgen that  portion  of the  applicable
one-time fee apportioned to such deliverable(s).

6. The  Confidential  Disclosure  Agreement dated October 1, 1997, as amended on
March 22,  1999 (the  "CDA"),  between  the  parties is  incorporated  herein by
reference.

7. Except as provided in the CDA,  neither party shall use the name of the other
party or make any press release or other disclosure of the existence or terms of
this Binding  Letter  Agreement  without the prior written  consent of the other
party.

8. This Binding Letter Agreement shall be governed by California law.

9. No  Amendment  or  modification  of this Binding  Letter  Agreement  shall be
effective  unless made in writing and signed by  authorized  representatives  of
each of the parties.

10.  Except as set forth in  paragraph 6 above,  this Binding  Letter  Agreement
constitutes  the entire  agreement  between the parties and supercedes all prior
and/or  contemporaneous  agreements and undertakings  between the parties,  both
written and oral, relating to the subject matter hereof.

                                       2

*** Confidential  portions omitted pursuant to a confidential  treatment request
submitted  pursuant to Rule 24b-2 under the Securities  Exchange Act of 1934, as
amended.  Omitted  portions have been filed  separately  with the Securities and
Exchange Commission.

<PAGE>

Please acknowledge your acceptance of the terms of this Binding Letter Agreement
by executing  where indicated  below.  Please sign both originals and return one
(1) original to my attention.

Sincerely,

/s/ Dennis Fenton
----------------------------------
Dennis Fenton
Senior Vice President

Operations and Process Development

Accepted and Agreed To:

Bioject Inc.

/s/ Jim O'Shea
----------------------------------
Jim O'Shea
Chairman, President and CEO

                                       3

*** Confidential  portions omitted pursuant to a confidential  treatment request
submitted  pursuant to Rule 24b-2 under the Securities  Exchange Act of 1934, as
amended.  Omitted  portions have been filed  separately  with the Securities and
Exchange Commission.

<PAGE>

                                  Schedule "A"

                              Bioject Deliverables

Due on or before August 31, 1999:

1.   Initial  development  specifications for the device that meet Amgen product
     profiles,  design  requirements  and  criteria.  The  package is to include
     individual specifications for each of the major device components:
     o Primary product storage container including
          -- Glass Cartridge
          -- Rubber Plunger
          -- Rubber Stopper
          -- Rubber O-Ring
     o Nozzle
     o Injector Body and Components
     o Gas Cartridge

2.   Updated plans and timelines for device development.
3.   Materials specifications.
4.   Initial CAD/Pro-Engineer based parts drawings.
5.   Updated Cost Estimates
6.   5 Design breadboard models  incorporating  Amgen industrial  design.  These
     models  are  not  required  to  be  functional;  however,  they  should  be
     representative  of actual product size,  shape weight and  appearance.  All
     customer interface mechanisms should be indicative of the working function.

Due on or before December 31, 1999:

1.   50  prototype  injectors   incorporating  Amgen  industrial  design.  These
     injectors will be  constructed  with part pieces created from a combination
     of prototype aluminum tooling and machining processes.  The devices will be
     manually assembled using appropriate fixtures and equipment.
2.   Product Testing Plan - Details on what testing is required and how it is to
     be implemented.  Plan should account for Functional  Testing,  ISO Testing,
     and Failure Modes Testing.
3.   Product  Assembly  Flow Plan -  Detailing  the entire  filling  and product
     assembly  process.  The plan should be divided into logical,  modular steps
     and account for logistics and sub-contractor activities.
4.   Assembly  Equipment  Procurement  Plan  -  Detailing  estimated  costs  and
     production lead-time for automated assembly equipment.

                                       4

*** Confidential  portions omitted pursuant to a confidential  treatment request
submitted  pursuant to Rule 24b-2 under the Securities  Exchange Act of 1934, as
amended.  Omitted  portions have been filed  separately  with the Securities and
Exchange Commission.<PAGE>   1
                                                                  EXHIBIT 4E (1)

                                 AMENDMENT NO. 1
                    TO FIVE YEAR CREDIT AGREEMENT AND WAIVER

         This Amendment No. 1 to Five Year Credit Agreement and Waiver (this
"Amendment") is entered into as of February 8, 1999, by and among Dexter
Corporation, a Connecticut corporation (the "Borrower"), The First National Bank
of Chicago, individually and as agent ("Agent"), and the other financial
institutions signatory hereto.

                                    RECITALS

         A. The Borrower, the Agent and the Lenders are party to that certain
five year credit agreement dated as of December 15, 1998 (the "Credit
Agreement"). Unless otherwise specified herein, capitalized terms used in this
Amendment shall have the meanings ascribed to them by the Credit Agreement.

         B. The Borrower, the Agent and the undersigned Required Lenders wish to
amend the Credit Agreement on the terms and conditions set forth below.

         Now, therefore, in consideration of the mutual execution hereof and
other good and valuable consideration, the parties hereto agree as follows:

                  1. Amendment to Credit Agreement. The Credit Agreement is
hereby amended as follows:

                           (a) Section 6.10(i) of the Credit Agreement is
         amended in its entirety to read as follows:

                  "(i) any Subsidiary may declare and pay dividends or make
                  distributions to its shareholders ratably relative to their
                  respective ownership interests in such Subsidiary and".

                  2. Consent and Waiver. The Required Lenders hereby waive any
Unmatured Default or Default existing under the Credit Agreement (including any
Unmatured Default or Default arising out of a breach of Sections 6.3(a) or
6.10(i)) which would not have arisen had this Amendment been in effect at all
times since December 15, 1998.

                  3. Representations and Warranties of the Borrower. The
Borrower represents and warrants that:

                           (a) The execution, delivery and performance by the
         Borrower of this Amendment have been duly authorized by all necessary
         corporate action and that this Amendment is a legal, valid and binding
         obligation of the Borrower enforceable against the Borrower in
         accordance with its terms, except as the enforcement thereof may be
         subject to the effect of any applicable bankruptcy, insolvency,
         reorganization, moratorium or similar law affecting creditors' rights
         generally;
<PAGE>   2
                           (b) Each of the representations and warranties
         contained in the Credit Agreement is true and correct in all material
         respects on and as of the date hereof as if made on the date hereof;

                           (c) After giving effect to this Amendment, no Default
         or Unmatured Default has occurred and is continuing.

                  4. Effective Date. This Amendment shall become effective upon
the execution and delivery hereof by the Borrower, the Agent and the Required
Lenders.

                  5. Reference to and Effect Upon the Credit Agreement.

                           (a) Except as specifically amended, the Credit
         Agreement and the other Loan Documents shall remain in full force and
         effect and are hereby ratified and confirmed.

                           (b) The execution, delivery and effectiveness of this
         Amendment shall not operate as a waiver of any right, power or remedy
         of the Agent or any Lender under the Credit Agreement or any Loan
         Document, nor constitute a waiver of any provision of the Credit
         Agreement or any Loan Document, except as specifically set forth
         herein. Upon the effectiveness of this Amendment, each reference in the
         Credit Agreement to "this Agreement", "hereunder", "hereof", "herein"
         or words of similar import shall mean and be a reference to the Credit
         Agreement as amended hereby.

                  6. Costs and Expenses.

                           The Borrower hereby affirms its obligation under
         Section 9.7 of the Credit Agreement to reimburse the Agent for all
         reasonable costs, internal charges and out-of-pocket expenses paid or
         incurred by the Agent in connection with the preparation, negotiation,
         execution and delivery of this Amendment, including but not limited to
         the attorneys' fees and time charges of attorneys for the Agent with
         respect thereto.

                  7. GOVERNING LAW. THIS AMENDMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS (AS OPPOSED TO CONFLICTS OF LAWS
PROVISIONS) OF THE STATE OF ILLINOIS BUT GIVING EFFECT TO FEDERAL LAWS
APPLICABLE TO NATIONAL BANKS.

                  8. Headings. Section headings in this Amendment are included
herein for convenience of reference only and shall not constitute a part of this
Amendment for any other purposes.

                  9. Counterparts. This Amendment may be executed in any number
of counterparts, each of which when so executed shall be deemed an original but
all such counterparts shall constitute one and the same instrument.

                           (signature page to follow)
<PAGE>   3
                  IN WITNESS WHEREOF, the parties have executed this Amendment
as of the date and year first above written.

                                  DEXTER CORPORATION
                                  By:       /s/ Dale J. Ribaudo
                                  Name:     Dale J. Ribaudo
                                  Title:    Treasurer

                                  THE FIRST NATIONAL BANK OF CHICAGO,
                                  Individually and as Agent
                                  By:       /s/ Tom Dao
                                  Name:     Tom Dao
                                  Title:    Corporate Banking Officer

                                  FLEET BANK,
                                  Individually and as Syndication Agent
                                  By:       /s/ Marlene R. Haddad
                                  Name:     Marlene R. Haddad
                                  Title:    Senior Vice President

                                  BANK OF AMERICA NATIONAL TRUST AND
                                  SAVINGS ASSOCIATION,
                                  Individually and as Documentation Agent
                                  By:       /s/ Donald J. Chin
                                  Name:     Donald J. Chin
                                  Title:    Managing Director

                                  ABN AMRO BANK N.V.,
                                  Individually and as Co-Agent
                                  By:       /s/ James S. Adelsheim
                                  Name:     James S. Adelsheim
                                  Title:    Group Vice President

                                  By:       /s/ David A. Carroll
                                  Name:     David A. Carroll
                                  Title:    Officer
<PAGE>   4
                                  BANKBOSTON, N.A.,
                                  Individually and as Co-Agent
                                  By: /s/ Harvey H. Thayer, Jr.
                                  Name: Harvey H. Thayer, Jr.
                                  Title: Managing Director

                                  BANCA COMMERCIALE ITALIANA,
                                  NEW YORK BRANCH,
                                  Individually and as Co-Agent
                                  By:       /s/ Charles Dougherty
                                  Name:     Charles Dougherty
                                  Title:    Vice President

                                  By:       /s/ Karen Purelis
                                  Name:     Karen Purelis
                                  Title:    Vice President

                                  THE BANK OF NEW YORK
                                  By:       /s/ Kenneth P. Sneider, Jr.
                                  Name:     Kenneth P. Sneider, Jr.
                                  Title:    Vice President

                                  WACHOVIA BANK, N.A.
                                  By:       /s/ Henry H. Hagan
                                  Name:     Henry H. Hagan
                                  Title:    Senior Vice President

                                  per pro BROWN BROTHERS HARRIMAN & CO.
                                  By:       /s/ Jared S. Keyes
                                  Name:     Jared S. Keyes
                                  Title:    Manager

                                  COMMERZBANK AG,
                                  Individually and as Co-Agent
                                  By:       /s/ Robert Donohue
                                  Name:     Robert Donohue
                                  Title:    Senior Vice President
<PAGE>   5
                                  By:       /s/ Peter Doyle
                                  Name:     Peter Doyle
                                  Title:    Assistant Vice President

                                  DEN DANSKE BANK AKTIESELSKAB,
                                  CAYMAN ISLANDS BRANCH,
                                  Individually and as Co-Agent
                                  By:       /s/ Peter L. Hargraves
                                  Name:     Peter L. Hargraves
                                  Title:    Vice President

                                  By:       /s/ John A. O'Neill
                                  Name:     John A. O'Neill
                                  Title:    Vice President

                                  FIRST UNION NATIONAL BANK,
                                  Individually and as Co-Agent
                                  By:       /s/ Stephen T. Dorosh
                                  Name:     Stephen T. Dorosh
                                  Title:    Vice President

                                  MELLON BANK, N.A.,
                                  Individually and as Co-Agent
                                  By:       /s/ Mark Ricci
                                  Name:     Mark Ricci
                                  Title:    Banking Officer

                                  SUNTRUST BANK, ATLANTA,
                                  Individually and as Co-Agent
                                  By:       /s/ W. David Wisdom
                                  Name:     W. David Wisdom
                                  Title:    Vice President

                                  By:       /s/ Robin R. Cowan
                                  Name:     Robin R. Cowan
                                  Title:    Operations Officer
<PAGE>   6
                                  BANQUE NATIONALE DE PARIS
                                  By:       /s/ Richard L. Sted
                                  Name:     Richard L. Sted
                                  Title:    Senior Vice President

                                  By:       /s/ Sophie Revillard Kaufman
                                  Name:     Sophie Revillard Kaufman
                                  Title:    Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]